fbpx

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
Manufacturer's illustration of how Keytruda stops cancer cells hiding from the immune system.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

A new study published in The Lancet finds Keytruda, the PD-1 antibody pembrolizumab, may offer a better safety profile but does not improve outcomes compared with paclitaxel.

Read Source
DonateMore InfoDonateMore Info
We cannot gather at a gala event this year, but a pandemic cannot stop us from joining together to ensure that the search to find a cure for gastric (stomach) cancer continues.

Join with us to fuel the next wave of progress.

Every contribution moves us closer to a cure.
Please join with us to fuel the next wave of progress. Together, we will defeat stomach cancer.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
X